SCHEMBL4027129

SCHEMBL4027129

CC(C(=O)O)c1noc(-c2ccc(F)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPH1 P17752 2/20 0.51
PPARG P37231 2/20 0.46
PPARA Q07869 2/20 0.46
PPARD Q03181 1/20 0.46
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
HDAC1 Q13547 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC8 Q9BY41 1/20 0.40
ATM Q13315 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CSGALNACT1 Q8TDX6 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14814648 0.81 NPC1 (0.47) TPH1PPARGPPARAPPARDNPC1
SCHEMBL10094548 0.81 MAOA (0.56) TPH1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL17452651 0.75 ALDH1A1 (0.47) TPH1PPARGPPARAPPARDNPC1
SCHEMBL2222200 0.73 HDAC8 (0.50) TPH1NPC1RAB9AHDAC1HDAC6
SCHEMBL11902286 0.73 HDAC1 (0.54) TPH1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL14814713 0.72 HDAC1 (0.50) TPH1PPARGPPARAPPARDNPC1
SCHEMBL8163626 0.71 TPH1 (0.61) TPH1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL1505380 0.71 TPH1 (0.61) TPH1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL25914377 0.71 TPH1 (0.45) TPH1PPARGPPARAPPARDNPC1
SCHEMBL16781384 0.70 PPARG (0.51) TPH1PPARGPPARAPPARDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560548-B2 Morpholin-acetamide derivatives for the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-07-14 US disclosed
US-20060079525-A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases ANCLIFF RACHAEL A 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079525-A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases ARG1, ARG2, NFKBIA TPH1 2094/4885PPARG 240/4885PPARA 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.